A phase I trial of in vivo gene therapy with the herpes simplex thymidine Kinase/Ganciclovir system for the treatment of refractory or recurrent ovarian cancer

Human Gene Therapy

Volumn 7, Issue 9, 1996, Pages 1161-1179

  Link Jr , C J ^a   Moorman, D ^a   Seregina, T ^a   Levy, J P ^a   Schabold, K J ^a  

^a IOWA METHODIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GANCICLOVIR; THYMIDINE KINASE;

CLINICAL TRIAL; FEMALE; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; RECURRENT CANCER; REVIEW; SIDE EFFECT; TUMOR BIOPSY;

HERPES; SIMPLEXVIRUS;

EID: 0029953781     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.9-1161     Document Type: Review

References (31)

1. BI, W.L., PARYSEK, L.M., WARNICK, R. and STAMBROOK, P.J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
2. CARUSO, M., PANIS, Y., GAGANDEEP, S., HOUSSIN, D., SALZMAN, J.L. and KLATZMANN, D. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. (USA) 90, 7024-7028.
3. CHEN, S.H., SHINE, H.D., GOODMAN, J.C. and WOO, S.L. (1994). Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. (USA) 91, 3054-3057.
4. CULVER, K.W., RAM, Z., WALBRIDGE, S., ISHII, H., OLDFIELD, E.H. and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
5. CULVER, K.W., VAN GILDER, J., LINK, C.J., CARLSTROM, T., BUROKER, T., YUH, W. and KOCH, K. (1994). Gene therapy for the treatment of malignant brain tumors within vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 343-379.
6. DAVIES, J. and SMITH, D.I. (1978). Plasmid-determined resistance to antimicrobial agents. Annu. Rev. Microbiol. 32, 469-518.
7. DEISSEROTH, A.B., KAVANAGH, J., and CHAMPLIN, R. (1993). Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoetic stem cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. NIH Recombinant DNA Advisory Committee, June, 1993.
8. EINZIG, A.I., WIERNIK, P.H., SASLOFF, J., GARL, S., RUNOWICZ, C., O'HANLAN, K.A. and GOLDBERG, G. (1990). Phase II study of taxol in patients with advanced ovarian cancer. Amer. Assoc. Cancer Res. Proc. 31, 187.
9. EZZEDDINE, Z.D., MARTUZA, R.L., PLATIKA, D., SHORT, M.P., MALICK, A., CHOI, B. and BREAKEFIELD, X.O. (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3, 608-614.
10. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L. and ABRAHAM, G.N. (1993). The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
11. FREEMAN, S.M., MCCUNE, C., ANGEL, C., ABRAHAM, G.N. and ABBOUD, C.N. (1992). Treatment of ovarian cancer using HSV-TK gene modified vaccine-regulatory issues. Hum. Gene Ther. 3, 342-346.
12. KOHN, E.C., SAROSY, G.A., BICHER, A., LINK, C.J., DAVIS, P., ADAMO, D., OGNIBENE, F. and REED, E. (1994). Phase II trial of high dose taxol in refractory ovarian cancer. J. Natl. Cancer Instit. 86, 18-24.
13. MCGUIRE, W.P., ROWINSKY, E.K., and ROSENSHEIN, N.B. (1989). Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111, 273-279.
14. MEYERS, C. (1984). The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin. Oncol. 11, 275-284.
15. MILLER, A.D. (1992). Retroviral vectors. Curr. Top. Microbiol. Immunol. 158, 1.
16. MILLER, A.D. and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Molec. Cell Biol. 6, 2895-2902.
17. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
18. MOOLTEN, F.L. and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297-300.
19. RAFFEL, C., CULVER, K.W., KOHN, D., NELSON, M., SIEGAL, S., GILLIS, F., LINK, C. and VILLABLANCA, J.G. (1994). Gene therapy for the treatment of recurrent pediatric malignant astrocytomas using in vivo transduction with the Herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 863-890.
20. RAM, Z., CULVER, K.W., OSHIRO, E.M., MOEN, R.C., DEVROOM, H.L., BLAESE, R.M. and OLDHELD, E.H. (1993). Gene therapy for malignant brain tumors: Preliminary results of a clinical study. Tenth International Conference on Brain Tumor Research and Therapy, Stalheim, Norway.
21. RAM, Z., WALBRIDGE, E., OSHIRO, E.M., VIOLA, J.J., CHIANG, Y., MUELLER, S.N., BLAESE, R.M. and OLDFIELD, E.H. (1994). Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res. 54, 2141-2145.
22. ROSENBERG, S.A., AEBERSOLD, P., CORNETTA, K., KASID, A., MORGAN, R., MOEN, R., KARSON, E., LOTZE, M.T., YANG, J.C., TOPALIAN, S., MERINO, M.J. CULVER, K., MILLER, A.D., BLAESE, R.M. and ANDERSON, W.F. (1990). Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570-578.
23. SHORT, M.P., CHOI, B.C., LEE, J.K., MALICK, A., BREAKEFIELD, X.O. and MARTUZA, R.L. (1990). Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27, 427-439.
24. SMYTHE, W.R., HWANG, H.M., AMIN, K.M., WILSON, J.M., KAISER, L.R. and ALBELDA, S.M. (1994). Gene therapy for human malignant mesothelioma utilizing adenoviral vector transfer of the HSV-thymidine kinase gene. Amer. J. Resp. Crit. Care Med. 149, A237.
25. STANKUS, B.J. (1992). Cytovene (ganciclovir sodium) product monograph. Syntex.
26. TAKAMIYA, Y., SHORT, M.P., MOOLTEN, F.L., FLEET, C., MINETA, T., BREAKEFIELD, X.O. and MARTUZA, R.L. (1993). An experimental model of retrovirus gene delivery for malignant brain tumors. J. Neurosurg. 79, 104-110.
27. TAPSCOTT, S.J., MILLER, A.D., OLSON, J.M., BERGER, M.S., GROUDINE, M. and SPENCE, A.M. (1994). Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci., USA 91, 8185-8189.
28. TEMIN, H.M. (1989). Retrovirus vectors: Promise and reality. Science. 246, 983.
29. THIGPEN, T., BLESSING, J., BALL, H., HUMMEL, S. and BARRET, R. (1990). Phase II Trial of Taxol as Second-Line Therapy for Ovarian Carcinoma. Amer. Soc. Clin. Oncol. Proc. 9, 156.
30. VERMA, I.M. (1990). Gene Therapy. Scientific American. November, 68-84.
31. YOUNG, R.C., PEREZ, C.A. and HOSKINS, W.J. (1993). Cancer of the ovary. In Cancer Principles and Practice of Oncology. V.T. DeVita Jr., S. Hellman and S.A. Rosenberg, eds. Philadelphia, (J.B. Lippincott) 4th ed. pp. 1226-1263.